(PRPO) Precipio, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRPO) Precipio, Inc. Complete Analysis Pack
Precipio's Business Model Canvas: How Diagnostics Drive Growth
Explore how Precipio, Inc. turns its diagnostic expertise into value, revenue, and growth. This concise Business Model Canvas breaks down the key partners, customer segments, and cost drivers behind the company’s strategy. Want the full strategic picture? Download the complete canvas for deeper insight.
Partnerships
Academic institutions in cancer research
Precipio works with academic institutions in cancer research to co-develop and validate blood cancer diagnostics, which helps sharpen assay performance and clinical relevance. These ties also add scientific credibility to Precipio’s testing platform, a key trust signal in a market where independent validation drives adoption.
Hospital and oncology laboratories
Hospitals and oncology laboratories are the main intake points for blood-cancer testing, so these partners help route samples into Precipio, Inc.’s diagnostic workflow and expand use of panels like HemeScreen. Blood cancers account for roughly 10% of new U.S. cancer cases each year, so access to these channels matters for volume and clinical adoption.
Biopharmaceutical customers
Precipio sells ICE-COLD PCR kits to biopharmaceutical customers, who use them in R&D to boost molecular test sensitivity. This adds a non-clinical revenue stream for Precipio’s patented platform and broadens demand beyond hospital testing.
Diagnostic reagent and supply partners
Precipio, Inc. depends on diagnostic reagent and supply partners to secure assay materials, media, and kit inputs that keep its cancer diagnostics and reagent products moving. These supplier ties help protect manufacturing and testing continuity when lead times, lot consistency, or regulated sourcing can disrupt operations.
Reliable partners also support product availability across both reagent sales and diagnostic workflows, which matters for a company that must keep test kits and lab inputs aligned with demand.
- Assay materials and media sourcing
- Kit production continuity
- Testing supply reliability
Clinical and research collaborators
Precipio, Inc. relies on clinical and research collaborators to validate blood cancer assays and turn lab findings into usable tests. These partners help speed adoption in specialized hematology settings, where even small validation studies can matter for clinical uptake.
- Validate blood cancer products
- Support new test adoption
- Expand specialized hematology reach
Precipio’s Partnerships Fuel Blood-Cancer Test Adoption
Precipio, Inc. depends on academic labs, hospitals, oncology labs, and research partners to validate and route its blood-cancer diagnostics. These ties support adoption of HemeScreen and ICE-COLD PCR, while keeping assay inputs and kit supply aligned with demand in a market where blood cancers are about 10% of new U.S. cases each year.
| Partner | Role | Data |
|---|---|---|
| Academic labs | Validate assays | Blood cancers 10% |
| Hospitals | Route samples | Panel adoption |
What is included in the product
Detailed Word Document
A concise Business Model Canvas capturing Precipio, Inc.’s strategy, customers, channels, and value creation.
Customizable Excel Spreadsheet
Quickly spot Precipio, Inc.’s key pain points and solutions in one editable business snapshot.
Reference Sources
Precipio, Inc. Reference Sources provide a traceable credibility trail that speeds due diligence and strengthens decision-making.
Activities
Blood cancer diagnostic testing
Precipio’s blood cancer diagnostic testing is a core clinical lab activity that links the Company directly to hematology and oncology care. Blood cancers still make up about 10% of new U.S. cancer cases, so this service sits in a large, recurring testing need rather than a one-off product sale.
Developing genetic diagnostic panels
HemeScreen is Precipio, Inc.’s genetic diagnostic panel suite, and building and refreshing these panels is a core activity. It needs nonstop assay design, validation, and clinical review to keep results relevant as hematologic variants and lab standards change.
Manufacturing reagents and kits
Precipio, Inc. makes diagnostic products, reagents, and ICE-COLD PCR kits, and that manufacturing work is central to its model because these are consumables that can drive repeat sales. The company’s 2025 filing shows this channel still anchors recurring revenue, so each kit and reagent shipment can feed follow-on demand.
Advancing ICE-COLD PCR technology
ICE-COLD PCR is Precipio, Inc.'s patented sensitivity platform, and in 2025-2026 the key activity is to protect the IP, refine assay performance, and expand use across clinical testing and biopharma. One platform, two growth engines.
- Protect patent rights
- Improve test sensitivity
- Commercialize in clinical and biopharma
Research collaboration and validation
Precipio, Inc. works with academic institutions on cancer research, diagnosis, and therapy, and those partnerships help test its products in real scientific settings before wider use. That kind of validation supports product credibility, speeds acceptance, and strengthens innovation in oncology diagnostics.
- Academic partners validate real-world performance.
- Collaboration supports adoption and product trust.
Precipio’s 2025-2026 Focus: Blood Cancer Testing and ICE-COLD PCR Growth
Precipio, Inc. focuses on blood cancer testing, HemeScreen panel upkeep, and ICE-COLD PCR kit and reagent manufacturing. In 2025-2026, the core work is assay design, validation, IP protection, and clinical and biopharma commercialization.
| Key activity | Data point |
|---|---|
| Blood cancer testing | ~10% of U.S. cancer cases |
| Revenue engine | 2025 recurring consumables sales |
| Platform focus | ICE-COLD PCR in 2025-2026 |
Full Document Unlocks After Purchase
Business Model Canvas
This Precipio, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a mockup or placeholder. What you see here is a live snapshot of the final file, with the same structure, formatting, and content. Once purchased, you’ll get full access to this same ready-to-use document, exactly as displayed.
Resources
ICE-COLD PCR patent
ICE-COLD PCR is one of Precipio, Inc. core proprietary assets, giving the Company a protected edge in sensitive molecular testing. The patent can support kit sales and also create licensing or other technology monetization paths, which matters for scaling beyond lab use.
IV-Cell cell culture media
IV-Cell cell culture media is Precipio, Inc.’s niche technical asset: one medium can grow 4 hematopoietic cell lineages at once, which helps blood-cancer and hematology labs run specialized workflows with fewer media changes and less process complexity.
That 4-lineage capability makes IV-Cell a clear differentiator in the portfolio, especially for hematology research and diagnostic use cases where cell-growth consistency and workflow speed matter.
HemeScreen genetic panels
HemeScreen is Precipio, Inc.'s core set of genetic diagnostic panels for blood cancers, and it acts as both a key intellectual asset and a commercial anchor for the Company's hematology testing line. By packaging multiple panels into one offering, HemeScreen helps support recurring diagnostic demand and strengthens Precipio, Inc.'s lab-based revenue model.
Laboratory and scientific expertise
Precipio, Inc. depends on specialized laboratory and molecular biology talent to develop, validate, and test regulated diagnostic products. In healthcare testing, trained scientific staff are the key resource because accuracy, compliance, and repeatability drive product approval and lab results.
- Supports assay development and validation
- Helps meet CLIA and FDA rules
- Protects test quality and reliability
Diagnostic infrastructure and IP
Precipio’s key resources are its lab infrastructure, testing workflows, and protected IP, which together let Company Name run clinical diagnostics and make products. These assets also support quality control, since the same validated systems that process samples can be used to scale manufacturing and protect assay know-how.
- Lab capacity supports clinical testing
- Workflows drive repeatable quality
- IP protects commercialization
Precipio’s IP and Lab Expertise Power Its Core Assays
Precipio's key resources are protected IP, lab workflows, and specialist staff, with ICE-COLD PCR, IV-Cell, and HemeScreen anchoring product and test monetization. These assets support regulated assay development, clinical testing, and licensing.
| Resource | Role |
|---|---|
| IP | Defends assays |
| Staff | Validate tests |
Value Propositions
Blood-cancer diagnostics focus
Precipio focuses on blood-cancer diagnostics, a high-need area that accounts for about 10% of new cancer cases worldwide. That niche gives labs and clinicians targeted tests for hematology cases instead of broad general panels, helping address faster, more precise detection where accuracy matters most.
Higher molecular sensitivity
ICE-COLD PCR raises molecular test sensitivity, helping detect rare targets that standard assays can miss. That matters most in oncology and advanced diagnostics, where even one missed signal can change care; global cancer cases reached about 20 million in 2022, underscoring the need for higher-detection tools.
Comprehensive genetic panels
HemeScreen’s comprehensive genetic panels give labs a broader view of actionable mutations and markers, so clinicians can make tighter diagnosis and therapy calls. Precipio says this multi-target approach supports faster, more complete hematologic workups and reduces the need to piece together results from separate tests.
Unique hematopoietic cell culture
IV-Cell gives Precipio, Inc. a clear edge in hematology research because one culture system can grow 4 hematopoietic cell lineages at the same time. That makes it useful for specialized blood-cell studies where standard media cannot support the same breadth of growth.
- 4 lineages in one system
- Supports research workflows
- Fits specialized hematology use
Clinical and research utility
Precipio’s clinical and research utility lets the same platform serve hospitals, reference labs, and biopharma teams, so one product line can support diagnosis and R&D workflows. That dual-use model broadens the addressable market and can improve revenue resilience when one end market slows.
- Supports clinical and research users
- Covers hospitals, labs, biopharma
- Expands market reach and use cases
Precipio’s Blood-Cancer Tests Aim for Faster, Sharper Diagnosis
Precipio, Inc. targets blood-cancer diagnostics with assays built for hematology, where precision matters most. Its ICE-COLD PCR and HemeScreen tools aim to find low-level targets and actionable mutations faster than broad, general panels.
| Value proposition | Data point |
|---|---|
| ICE-COLD PCR | Higher sensitivity for rare targets |
| HemeScreen | Broader mutation profiling |
| IV-Cell | 4 cell lineages in one system |
Customer Relationships
B2B scientific support
Precipio’s B2B scientific support covers 3 core customer groups: laboratories, academic institutions, and biopharma clients. For complex diagnostic tools, direct technical help and clear product guidance are key to adoption and routine use, especially when workflows must fit regulated lab settings.
Collaborative development ties
In FY2025, Precipio’s collaborative development ties with academic institutions focus on co-developing and validating cancer research and diagnosis tools in real lab settings. That keeps products close to scientific and clinical needs, where accuracy, reproducibility, and validation drive adoption.
Long-term account management
Precipio, Inc.’s diagnostic and reagent sales depend on recurring lab accounts, so long-term account management is key to retention. In its latest filings, the Company showed continued dependence on repeat product use and specialized customers, making sustained communication and service essential to keep accounts active over time.
Validation and implementation support
Precipio, Inc. ties customer relationships to validation and implementation support because new assays and workflow changes often need hands-on setup, interpretation help, and lab integration. That support lowers adoption friction and helps customers move from trial to routine use.
- Setup support speeds adoption
- Workflow integration reduces errors
- Interpretation help builds trust
Trust-based clinical relationships
Precipio’s customer ties in blood-cancer diagnostics depend on trust, since healthcare buyers expect reliable, consistent results in a tightly regulated market. Blood cancers make up about 10% of all new cancer cases in the U.S., so even small errors can damage adoption and repeat use.
- Reliability drives repeat lab use.
- Quality matters more under regulation.
- Trust is critical in blood-cancer testing.
Hands-On Support Keeps Precipio’s Lab Customers Coming Back
Precipio, Inc. keeps customer relationships hands-on: labs need setup help, workflow integration, and assay interpretation to move from trial to routine use. In FY2025, repeat lab accounts and regulated blood-cancer testing made trust, accuracy, and fast technical support the main drivers of retention.
| Driver | Why it matters |
|---|---|
| Hands-on support | Speeds adoption |
| Repeat accounts | Supports recurring use |
| Blood-cancer focus | Trust is critical |
Channels
Direct sales to laboratories
Precipio sells direct to laboratories through its own sales team, which fits specialty diagnostics because buyers often need technical guidance and product-specific setup. Direct selling also helps place products faster in niche labs, where the U.S. CLIA system covers more than 320,000 certified testing sites.
Clinical laboratory workflow
Precipio, Inc.’s clinical laboratory workflow is the core service channel: providers send blood-cancer samples, and laboratory operations plus sample processing turn them into diagnostic reports. In 2025, this route stayed central to the service business because it directly connects ordering clinicians to testing and result delivery.
Academic and research partnerships
Academic and research partnerships are a direct channel for Precipio, Inc., helping place products in university and lab settings where validation starts. In FY2025, these settings matter most for moving from scientific use to broader clinical and commercial adoption, because early research use can speed later market trust.
Biopharma distribution for kits
Precipio, Inc. sells ICE-COLD PCR kits through a direct B2B channel to biopharmaceutical customers, supporting drug development and molecular research. This channel fits lab buyers that want fast, reliable kit supply for assay validation, biomarker work, and targeted testing.
- Direct sales to biopharma labs
- Supports R&D and molecular workflows
- Kit demand tied to research use
Digital and company communication
Precipio, Inc. leans on its corporate website and direct outreach because specialty diagnostics sell through education first. The site can explain IV-Cell and HemeScreen in plain terms, then move lab leaders into demos, sample requests, and sales follow-up.
- Website builds product trust
- Direct outreach drives lead generation
- Content supports clinician education
- Best for niche healthcare buyers
Precipio’s Direct-Sales Model Powers Niche Diagnostics Reach
Precipio, Inc. uses direct sales, its lab workflow, and web-led outreach to move niche diagnostics into clinician and lab hands. In FY2025, this mattered most for blood-cancer testing and ICE-COLD PCR kits, while the U.S. CLIA network covered more than 320,000 certified testing sites.
| Channel | Use | FY2025 data |
|---|---|---|
| Direct sales | Lab and biopharma buyers | 320,000+ CLIA sites |
Customer Segments
Hematology and oncology laboratories
Hematology and oncology laboratories are core users of blood-cancer diagnostics, where targeted panels and reliable molecular methods drive daily testing. Precipio’s specialized workflow tools fit this niche, supporting labs that need fast, accurate detection for leukemia, lymphoma, and related disorders.
Hospitals and health systems
Hospitals and health systems are institutional buyers across roughly 6,100 U.S. hospitals, and they need recurring diagnostic testing plus lab support for inpatients and referrals. Blood cancers account for about 10% of cancer diagnoses, so larger systems are a strong fit for Precipio, Inc.’s hematology-focused testing and related laboratory services.
Academic research institutions
Academic research institutions are a key Precipio customer, including universities and cancer research groups that need advanced tools for diagnosis and therapy research, plus assay validation and scientific evaluation. U.S. cancer research funding stays large, with the National Cancer Institute at about $7.3 billion in FY2025, which supports steady demand for high-quality research assays.
Biopharmaceutical companies
Biopharmaceutical companies buy ICE-COLD PCR kits for R&D and molecular testing, where high sensitivity can make a real difference. In a global biopharma R&D market still above $200 billion a year, buyers pay for technical performance and reliable detection in low-abundance samples.
- Used in R&D workflows
- Used in molecular testing
- Sensitivity drives purchase decisions
Clinical diagnostics users
Clinical diagnostics users include hematology labs and providers that need fast, accurate support for blood cancer testing. In the U.S., about 186,000 people are expected to be diagnosed with leukemia, lymphoma, or myeloma each year, which keeps demand high for precise review tools and lab services.
- Hematology labs
- Blood cancer providers
- Accurate diagnostic support
- Precipio products fit this need
Precipio’s Core Customers and Growth Drivers
Precipio, Inc. sells mainly to hematology and oncology labs, hospitals, academic cancer centers, and biopharma teams that need accurate blood-cancer testing and assay validation. Demand is supported by about 6,100 U.S. hospitals, $7.3 billion of National Cancer Institute FY2025 funding, and roughly 186,000 annual U.S. leukemia, lymphoma, and myeloma diagnoses.
| Customer segment | Why it buys |
|---|---|
| Hematology labs | Fast, accurate diagnostics |
| Hospitals | Recurring inpatient testing |
| Academic centers | Research and validation |
| Biopharma | R&D molecular testing |
Cost Structure
Research and development spend
Precipio, Inc. treats research and development as a core cost because diagnostics need constant assay innovation, validation, and platform upgrades. For proprietary tools like ICE-COLD PCR, R&D is not optional; it protects product performance and future margins.
Laboratory operations
Laboratory operations are a core Precipio, Inc. cost line because each blood-cancer test depends on lab staff, analyzers, reagents, and consumables, plus ongoing quality control. In clinical labs, consumables and reagents often make up a large share of per-test cost, so volume and test mix matter a lot for gross margin.
These costs rise and fall with test volume, but they stay central because every report must meet clinical accuracy standards. For a diagnostics business like Precipio, Inc., tighter throughput and lower waste can have an outsized impact on operating leverage.
Regulatory and compliance costs
Regulatory and compliance costs for Precipio, Inc. are tied to CLIA, CAP, and FDA-grade quality systems, so every test must be documented, validated, and monitored for accuracy. In diagnostics, these costs are not optional; they protect market access, support clinical trust, and can consume a meaningful share of operating spend in a tightly regulated market.
Manufacturing and materials
Manufacturing and materials are a core cost driver for Precipio, Inc., because IV-Cell, HemeScreen products, and ICE-COLD PCR kits all need raw inputs, lab prep, and quality control. For a small diagnostics maker, supply reliability matters as much as unit cost: any delay or shortage can lift gross margin pressure and slow deliveries to labs.
- Raw materials drive reagent cost.
- Kit assembly adds labor and QC.
- Supply gaps hurt margin and timing.
Sales, support, and personnel
Precipio, Inc.’s sales, support, and personnel costs should stay heavy because specialized B2B selling and technical support need skilled people, not just software. For a company with a small base, payroll for scientific, commercial, and operations staff can take a large share of spend, especially when each account needs hands-on support.
- Specialized sales is labor-heavy
- Technical support needs scientific staff
- Personnel costs likely drive spend
Precipio’s Costs Stay High Across R&D, Labs, and Compliance
Precipio, Inc.’s biggest costs are R&D, lab operations, compliance, materials, and specialized staff. Cost of revenue and SG&A stay tied to test volume, while assay validation and quality systems keep spend high even when sales are uneven.
| Cost line | Driver |
|---|---|
| R&D | Assay and platform upgrades |
| Lab ops | Reagents, staff, QC |
| Compliance | CLIA, CAP, FDA controls |
Revenue Streams
Diagnostic testing fees
Precipio’s diagnostic testing fees are its core clinical revenue, coming from blood-cancer testing for hospitals and labs. The stream rises with sample volumes and test demand; Precipio reported roughly $7 million in annual revenue in its latest public filings, so each added test directly lifts fee income.
Reagent and product sales
Precipio, Inc. sells diagnostic products and reagents, and these consumables create recurring revenue because customers must keep buying them to run the company’s testing platforms. In FY2025, this line stayed tied to platform use, so each installed account can keep generating follow-on sales.
ICE-COLD PCR kit sales
ICE-COLD PCR kit sales give Precipio, Inc. a separate product revenue stream from biopharmaceutical customers, so sales are not tied only to clinical testing volume. It also turns the company’s patented ICE-COLD PCR technology into a monetized product line, broadening margin potential beyond lab services.
IV-Cell and HemeScreen commercialization
IV-Cell and HemeScreen are direct revenue drivers because Precipio, Inc. sells them into specialty pathology workflows, where product placement can turn into repeat test-use revenue. In Precipio, Inc.'s latest public filings, this specialty lab focus remained the core commercial engine, with revenue tied to adoption in diagnostic settings and sticky workflow use.
- Product sales and placement
- Workflow-driven repeat use
- Specialty diagnostics focus
Collaborative and service-based income
Precipio, Inc. earns collaborative and service-based income through academic and research partnerships that can bring in service fees and project revenue. Validation work and development support add another paid stream, which fits its research-linked model and can complement product sales.
- Academic partnerships
- Validation service fees
- Development support income
Precipio’s Revenue Engine: Diagnostics First, Recurring Sales Follow
Precipio, Inc. makes most revenue from diagnostic testing fees and product sales tied to its blood-cancer workflow, with FY2025 revenue at about $7 million. Recurring consumables and kit sales, including ICE-COLD PCR, IV-Cell, and HemeScreen, add follow-on income as customers keep using the platforms.
| Revenue stream | FY2025 |
|---|---|
| Diagnostic testing fees | Core driver |
| Product and reagent sales | Recurring |
| ICE-COLD PCR kits | Separate product line |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.